Powder: -20°C for 3 years | In solvent: -80°C for 1 year
hCAI/II-IN-6 是一种具有选择性和口服活性的human carbonic anhydrase(CA) 抑制剂。hCAI/II-IN-6对 hCA I,hCA II,hCA VII 和 hCA XII 有抑制作用,Ki 值分别为 220,4.9,6.5 和 >50000 nM。hCAI/II-IN-6 在体内显示抗惊厥活性。hCAI/II-IN-6 可以用于研究癫痫。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 243 | 现货 | ||
5 mg | ¥ 563 | 现货 | ||
10 mg | ¥ 897 | 现货 | ||
25 mg | ¥ 1,860 | 现货 | ||
50 mg | ¥ 2,970 | 现货 | ||
100 mg | ¥ 4,790 | 现货 | ||
500 mg | ¥ 9,880 | 现货 |
产品描述 | hCAI/II-IN-6 is a selective and orally active inhibitor of human carbonic anhydrase (CA). hCAI/II-IN-6 inhibited hCA I, hCA II, hCA VII, and hCA XII with Ki values of 220, 4.9, 6.5, and >50,000 nM. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy. |
靶点活性 | CA XII (human):>50000 nM(Ki ), CA VII (human):6.5 nM(Ki ), CA (human):220 nM(Ki ), CA II (human):4.9 nM(Ki ) |
体外活性 | hCAI/II-IN-6 (0-50 μM) displays inhibitory effects on the activities of hCA I, hCA II, hCA VII, and hCA XII, exhibiting Ki values of 220 nM, 4.9 nM, 6.5 nM, and >50000 nM, respectively.[1] |
体内活性 |
In vivo, hCAI/II-IN-6 (30-100mg/kg; i.p. once; Swiss albino mice) provided seizure attenuation and good anticonvulsant effect and showed an ED 50 of 13.7mg/kg in anticonvulsant quantification study. [1] In vivo, hCAI/II-IN-6 (30 mg/kg; p.o.; once; Swiss albino mice) has been observed to possess anti-MES (maximal electroshock seizure) activity.[1] |
分子量 | 388.48 |
分子式 | C19H24N4O3S |
CAS No. | 694466-00-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 225.0 mg/mL (579.2 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5741 mL | 12.8707 mL | 25.7414 mL | 64.3534 mL |
5 mM | 0.5148 mL | 2.5741 mL | 5.1483 mL | 12.8707 mL | |
10 mM | 0.2574 mL | 1.2871 mL | 2.5741 mL | 6.4353 mL | |
20 mM | 0.1287 mL | 0.6435 mL | 1.2871 mL | 3.2177 mL | |
50 mM | 0.0515 mL | 0.2574 mL | 0.5148 mL | 1.2871 mL | |
100 mM | 0.0257 mL | 0.1287 mL | 0.2574 mL | 0.6435 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
hCAI/II-IN-6 694466-00-7 Metabolism Carbonic Anhydrase Inhibitor inhibitor inhibit